Janone (ALTS) Competitors $6.60 -0.35 (-5.04%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$6.77 +0.17 (+2.58%) As of 02/21/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrends ALTS vs. PRME, MNPR, ATYR, TRVI, ALLO, CMPS, OLMA, FHTX, TNGX, and VYGRShould you be buying Janone stock or one of its competitors? The main competitors of Janone include Prime Medicine (PRME), Monopar Therapeutics (MNPR), Atyr PHARMA (ATYR), Trevi Therapeutics (TRVI), Allogene Therapeutics (ALLO), COMPASS Pathways (CMPS), Olema Pharmaceuticals (OLMA), Foghorn Therapeutics (FHTX), Tango Therapeutics (TNGX), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry. Janone vs. Prime Medicine Monopar Therapeutics Atyr PHARMA Trevi Therapeutics Allogene Therapeutics COMPASS Pathways Olema Pharmaceuticals Foghorn Therapeutics Tango Therapeutics Voyager Therapeutics Prime Medicine (NYSE:PRME) and Janone (NASDAQ:ALTS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations. Which has better earnings and valuation, PRME or ALTS? Janone has higher revenue and earnings than Prime Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime MedicineN/AN/A-$198.13M-$2.05-1.44Janone$39.61M2.34-$7.81MN/AN/A Does the media refer more to PRME or ALTS? In the previous week, Prime Medicine and Prime Medicine both had 1 articles in the media. Prime Medicine's average media sentiment score of 0.00 equaled Janone'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Janone 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of PRME or ALTS? 70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 6.3% of Janone shares are owned by institutional investors. 23.5% of Prime Medicine shares are owned by company insiders. Comparatively, 4.9% of Janone shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in PRME or ALTS? Prime Medicine received 22 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformPrime MedicineOutperform Votes2261.11% Underperform Votes1438.89% JanoneN/AN/A Is PRME or ALTS more profitable? Prime Medicine's return on equity of -107.87% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Janone N/A -2,940.01%-39.81% Do analysts rate PRME or ALTS? Prime Medicine currently has a consensus target price of $13.13, suggesting a potential upside of 343.41%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities research analysts plainly believe Prime Medicine is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, PRME or ALTS? Prime Medicine has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, Janone has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. SummaryPrime Medicine beats Janone on 8 of the 12 factors compared between the two stocks. Get Janone News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricJanonePharmaceutical IndustryFinance SectorNASDAQ ExchangeMarket Cap$92.86M$7.07B$11.65B$9.02BDividend YieldN/A2.77%5.38%3.84%P/E RatioN/A3.9223.2816.68Price / Sales2.34314.2826.4785.13Price / CashN/A67.8318.2037.32Price / Book-9.856.752.594.65Net Income-$7.81M$138.11M$1.03B$245.69M7 Day Performance-4.35%-2.54%-1.40%-2.67%1 Month Performance36.36%-2.00%0.68%-2.16%1 Year PerformanceN/A-5.04%14.94%12.90% Janone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSJanoneN/A$6.60-5.0%N/AN/A$97.78M$39.61M0.00170News CoveragePRMEPrime Medicine2.5356 of 5 stars$2.42-2.0%$13.13+442.4%-65.1%$317.41MN/A-1.18234News CoverageMNPRMonopar Therapeutics0.9201 of 5 stars$51.89+7.1%$43.00-17.1%+1,312.3%$316.53MN/A-26.3410ATYRAtyr PHARMA2.8166 of 5 stars$3.77-3.3%$19.25+410.6%N/A$316.45M$350,000.00-4.0153Analyst ForecastAnalyst RevisionNews CoverageGap UpTRVITrevi Therapeutics2.7542 of 5 stars$4.06-4.2%$9.31+129.4%+73.6%$312.09MN/A-9.2320News CoveragePositive NewsGap UpALLOAllogene Therapeutics2.8268 of 5 stars$1.48-2.0%$9.73+557.7%-51.1%$310.31M$90,000.00-0.95310CMPSCOMPASS Pathways1.7 of 5 stars$4.47+1.4%$33.60+651.7%-57.6%$305.84MN/A-2.03120OLMAOlema Pharmaceuticals3.2669 of 5 stars$5.16-9.3%$28.75+457.2%-64.0%$295.67MN/A-2.3670FHTXFoghorn Therapeutics2.6981 of 5 stars$5.29+11.4%$13.17+148.9%-12.4%$294.18M$34.15M-2.76120Positive NewsHigh Trading VolumeTNGXTango Therapeutics3.4582 of 5 stars$2.73-9.9%$13.14+381.4%-78.7%$293.26M$36.53M-2.3190VYGRVoyager Therapeutics4.5304 of 5 stars$5.32-1.8%$15.97+200.1%-44.8%$290.61M$163.78M7.49100Upcoming EarningsNews Coverage Related Companies and Tools Related Companies PRME Alternatives MNPR Alternatives ATYR Alternatives TRVI Alternatives ALLO Alternatives CMPS Alternatives OLMA Alternatives FHTX Alternatives TNGX Alternatives VYGR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALTS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janone Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALTS Stock Alerts